You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Antagonist of 5-HT2A and dopamine D2 receptors (Ki values are 4 and 11 nM respectively). Also displays affinity for a range of other receptors including D1 and D4, 5-HT2C, α1, H1 and M1-4 receptors (Ki values range between 1.9 and 31 nM). Atypical antipsychotic. Displays anticholinergic properties. Also a highly potent activator of hM4Di DREADDs (EC50 values are 5 nM in vitro and 7 nM in vivo).
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 312.43. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.2 mL||16 mL||32.01 mL|
|5 mM||0.64 mL||3.2 mL||6.4 mL|
|10 mM||0.32 mL||1.6 mL||3.2 mL|
|50 mM||0.06 mL||0.32 mL||0.64 mL|
References are publications that support the biological activity of the product.
Tollefson and Taylor (2000) Olanzapine: preclinical and clinical profiles of a novel antipsychotic agent. CNS Drug Reviews 6 303
Moore et al (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J.Pharmacol.Exp.Ther. 262 545 PMID: 1354253
Bymaster et al (1996) Radioreceptor binding profile of the atypical antipsychotic olanz. Neuropsychopharmacology 14 87 PMID: 8822531
If you know of a relevant reference for Olanzapine, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Olanzapine, Olanzapine supplier, 5ht2a, 5ht2c, serotonergics, dopamine, dopaminergics, d2, antagonists, atypical, antipsychotics, thienobenzodiazepine, chemogenetics, D2, Receptors, DREADDs, 5-HT2A, 4349, Tocris Bioscience
3 Citations for Olanzapine
Citations are publications that use Tocris products. Selected citations for Olanzapine include:
Joshi and Panicker (2019) Identifying the In Vivo Cellular Correlates of Antipsychotic Drugs. Eneuro 5 PMID: 30713996
Pérez-Gómez et al (2018) A phenotypic Caenorhabditis elegans screen identifies a selective suppressor of antipsychotic-induced hyperphagia. Nat Commun 9 5272 PMID: 30532051
Czysz et al (2015) Lateral diffusion of Gαs in the plasma membrane is decreased after chronic but not acute antidepressant treatment: role of lipid raft and non-raft membrane microdomains. Nat Methods 40 766 PMID: 25249058
Do you know of a great paper that uses Olanzapine from Tocris? Please let us know.
Reviews for Olanzapine
There are currently no reviews for this product. Be the first to review Olanzapine and earn rewards!
Have you used Olanzapine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.